Treating mice lacking superoxide dismutase 2 (SOD2) with catalytic antioxidant could decrease the levels of AD-associated tau hyperphosphorylation, which indicates that mitochondrial oxidative stress contributes to abnormal hyperphosphorylation of tau (Melov et al., 2007). The gene discussed is MAPT; the disease is Alzheimer disease.